Upregulation of Flotillin-1 predicts poor prognosis and promotes malignant progression, proliferation and metastasis of multiple tumors, including non-small cell lung, breast cancer, renal cell carcinoma, neuroblastoma, bladder cancer, prostate cancer and hepatocellular carcinoma (Li et al., 2014a; Lin et al., 2011; Zhang et al., 2014; Tomiyama et al., 2014; Guan et al., 2014; Jang et al., 2019; Zhang et al., 2013). Here, FLOT1 is linked to breast carcinoma.